345 related articles for article (PubMed ID: 16631684)
1. Lamivudine prophylaxis for hepatitis B virus infection after lung transplantation.
Shitrit AB; Kramer MR; Bakal I; Morali G; Ben Ari Z; Shitrit D
Ann Thorac Surg; 2006 May; 81(5):1851-2. PubMed ID: 16631684
[TBL] [Abstract][Full Text] [Related]
2. Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation.
Castells L; Vargas V; Rodríguez F; Allende H; Buti M; Sánchez-Avila JF; Jardí R; Margarit C; Pumarola T; Esteban R; Guardia J
Liver Transpl; 2002 Oct; 8(10):892-900. PubMed ID: 12360430
[TBL] [Abstract][Full Text] [Related]
3. Transmission of hepatitis B infection from hepatitis B core antibody--positive liver allografts is prevented by lamivudine therapy.
Yu AS; Vierling JM; Colquhoun SD; Arnaout WS; Chan CK; Khanafshar E; Geller SA; Nichols WS; Fong TL
Liver Transpl; 2001 Jun; 7(6):513-7. PubMed ID: 11443579
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.
Giaccone L; Festuccia M; Marengo A; Resta I; Sorasio R; Pittaluga F; Fiore F; Boccadoro M; Rizzetto M; Bruno B; Marzano A
Biol Blood Marrow Transplant; 2010 Jun; 16(6):809-17. PubMed ID: 20060484
[TBL] [Abstract][Full Text] [Related]
5. Discontinuation of lamivudine treatment for hepatitis flare after kidney or heart transplantation in hepatitis B surface antigen-positive patients: A retrospective case series.
Huang YW; Liu CJ; Lai MY; Lee PH; Tsai MK; Wang SS; Lai MK; Kao JH
Clin Ther; 2006 Sep; 28(9):1327-34. PubMed ID: 17062306
[TBL] [Abstract][Full Text] [Related]
6. Reactivation of hepatitis and lamivudine therapy in 11 HBsAg-positive renal allograft recipients: a single centre experience.
Murakami R; Amada N; Sato T; Orii T; Kikuchi H; Haga I; Ohashi Y; Okazaki H
Clin Transplant; 2006; 20(3):351-8. PubMed ID: 16824154
[TBL] [Abstract][Full Text] [Related]
7. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients.
Chan TM; Fang GX; Tang CS; Cheng IK; Lai KN; Ho SK
Hepatology; 2002 Nov; 36(5):1246-52. PubMed ID: 12395336
[TBL] [Abstract][Full Text] [Related]
8. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors.
Prakoso E; Strasser SI; Koorey DJ; Verran D; McCaughan GW
Clin Transplant; 2006; 20(3):369-73. PubMed ID: 16824156
[TBL] [Abstract][Full Text] [Related]
9. Lamivudine prophylaxis and treatment of hepatitis B Virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab.
Moses SE; Lim ZY; Sudhanva M; Devereux S; Ho AY; Pagliuca A; Zuckerman M; Mufti GJ
J Med Virol; 2006 Dec; 78(12):1560-3. PubMed ID: 17063522
[TBL] [Abstract][Full Text] [Related]
10. Lamivudine monoprophylaxis for de novo HBV infection in HBsAg-negative recipients with HBcAb-positive liver grafts.
Vizzini G; Gruttadauria S; Volpes R; D'Antoni A; Pietrosi G; Filì D; Petridis I; Pagano D; Tuzzolino F; Santonocito MM; Gridelli B
Clin Transplant; 2011; 25(1):E77-81. PubMed ID: 21039887
[TBL] [Abstract][Full Text] [Related]
11. An open-label study of lamivudine for chronic hepatitis B in six patients with chronic renal failure before and after kidney transplantation.
Ben-Ari Z; Broida E; Kittai Y; Chagnac A; Tur-Kaspa R
Am J Gastroenterol; 2000 Dec; 95(12):3579-83. PubMed ID: 11151895
[TBL] [Abstract][Full Text] [Related]
12. [Post-transplant prophylaxis of the recurrence of lamivudine-resistant YMDD mutant hepatitis B virus in liver recipients].
Yang Y; Yang Y; Zhang J; Yi HM; Lu MQ; Cai CJ; Li X; Jiang N; Xu C; Li H; Wang GS; Yi SH; Zhang JF; Jiang H; Yang Q; Chen GH
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Oct; 28(10):1810-2. PubMed ID: 18971179
[TBL] [Abstract][Full Text] [Related]
13. Lamivudine therapy in kidney allograft recipients who are seropositive for hepatitis B surface antigen.
Filik L; Karakayali H; Moray G; Dalgiç A; Emiroğlu R; Ozdemir N; Colak T; Gür G; Yilmaz U; Haberal M
Transplant Proc; 2006 Mar; 38(2):496-8. PubMed ID: 16549158
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of hepatitis B virus infection with Lamivudine after heart transplantation.
Wang SS; Chou NK; Chi NH; Hsu RB; Huang SC; Chen YS; Yu HY; Tsao CI; Ko WJ; Lai MY; Chu SH
Transplant Proc; 2006 Sep; 38(7):2138-40. PubMed ID: 16980024
[TBL] [Abstract][Full Text] [Related]
15. Residual hepatitis B virus particles in liver transplant recipients receiving lamivudine: PCR quantitation of HBV DNA and ELISA of preS1 antigen.
Petit MA; Buffello-Le Guillou D; Roche B; Dussaix E; Duclos-Vallée JC; Féray C; Samuel D
J Med Virol; 2001 Nov; 65(3):493-504. PubMed ID: 11596084
[TBL] [Abstract][Full Text] [Related]
16. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population.
Prieto M; Gómez MD; Berenguer M; Córdoba J; Rayón JM; Pastor M; García-Herola A; Nicolás D; Carrasco D; Orbis JF; Mir J; Berenguer J
Liver Transpl; 2001 Jan; 7(1):51-8. PubMed ID: 11150423
[TBL] [Abstract][Full Text] [Related]
17. Failure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B.
Lo CM; Liu CL; Chan SC; Lau GK; Fan ST
J Hepatol; 2005 Aug; 43(2):283-7. PubMed ID: 15964658
[TBL] [Abstract][Full Text] [Related]
18. Lamivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin's lymphoma single institution experience.
Huang H; Cai Q; Lin T; Lin X; Liu Y; Gao Y; Peng R
Expert Opin Pharmacother; 2009 Oct; 10(15):2399-406. PubMed ID: 19761353
[TBL] [Abstract][Full Text] [Related]
19. Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients.
Hsiao LT; Chiou TJ; Liu JH; Chu CJ; Lin YC; Chao TC; Wang WS; Yen CC; Yang MH; Tzeng CH; Chen PM
Biol Blood Marrow Transplant; 2006 Jan; 12(1):84-94. PubMed ID: 16399572
[TBL] [Abstract][Full Text] [Related]
20. Acceptable recipient outcomes with the use of hearts from donors with hepatitis-B core antibodies.
Pinney SP; Cheema FH; Hammond K; Chen JM; Edwards NM; Mancini D
J Heart Lung Transplant; 2005 Jan; 24(1):34-7. PubMed ID: 15653376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
